Literature DB >> 15026329

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.

Katerina V Gurova1, Jason E Hill, Olga V Razorenova, Peter M Chumakov, Andrei V Gudkov.   

Abstract

Renal cell carcinoma (RCC) rarely acquires mutations in p53 tumor suppressor gene, suggesting that p53 signaling in this tumor type might be repressed by some other mechanism. In fact, all four RCC-derived cell lines we tested maintained wild-type p53 but were not capable of transactivating p53-responsive reporters and endogenous p53-responsive genes. p53 protein in RCC showed normal response to genotoxic stress, including accumulation, nuclear translocation, and activation of specific DNA binding. Functional and expression analysis of Mdm2, MdmX, and Arf showed lack of involvement of these p53 regulators in the observed defect of p53 function in RCC. However, activation of p53-mediated transactivation could be achieved by extremely high levels of p53 attained by lentivirus vector-driven transduction, suggesting the involvement of a dominant inhibitor in repression of p53-dependent transactivation in RCC. Consistently, p53 inactivation prevailed in the hybrids of RCC cells with the cells possessing fully functional p53. Remarkably, cells of normal kidney epithelium also caused partial p53 repression in cell fusion experiments, suggesting that RCC-specific p53 repression may be based on an unknown dominant mechanism also acting in normal kidney tissue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026329     DOI: 10.1158/0008-5472.can-03-1541

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Authors:  Alexander V Gasparian; Catherine A Burkhart; Andrei A Purmal; Leonid Brodsky; Mahadeb Pal; Madhi Saranadasa; Dmitry A Bosykh; Mairead Commane; Olga A Guryanova; Srabani Pal; Alfiya Safina; Sergey Sviridov; Igor E Koman; Jean Veith; Anton A Komar; Andrei V Gudkov; Katerina V Gurova
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Authors:  Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

3.  Analysis of nondegradative protein ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin.

Authors:  Haopeng Wang; Atsushi Matsuzawa; Scott A Brown; JingRan Zhou; Cliff S Guy; Ping-Hui Tseng; Karen Forbes; Thomas P Nicholson; Paul W Sheppard; Hans Häcker; Michael Karin; Dario A A Vignali
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-17       Impact factor: 11.205

4.  Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.

Authors:  Henry Garcia; Jeffrey C Miecznikowski; Alfiya Safina; Mairead Commane; Anja Ruusulehto; Sami Kilpinen; Robert W Leach; Kristopher Attwood; Yan Li; Seamus Degan; Angela R Omilian; Olga Guryanova; Olympia Papantonopoulou; Jianmin Wang; Michael Buck; Song Liu; Carl Morrison; Katerina V Gurova
Journal:  Cell Rep       Date:  2013-07-03       Impact factor: 9.423

5.  Stress-sensitive regulation of IFRD1 mRNA decay is mediated by an upstream open reading frame.

Authors:  Chenyang Zhao; Shyamasree Datta; Palash Mandal; Shuqing Xu; Thomas Hamilton
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

Review 6.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Down-regulation of p53 by double-stranded RNA modulates the antiviral response.

Authors:  Joao T Marques; Dominique Rebouillat; Chilakamarti V Ramana; Junko Murakami; Jason E Hill; Andrei Gudkov; Robert H Silverman; George R Stark; Bryan R G Williams
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.

Authors:  Sivakumar Vallabhapurapu; Atsushi Matsuzawa; Weizhou Zhang; Ping-Hui Tseng; Jonathan J Keats; Haopeng Wang; Dario A A Vignali; P Leif Bergsagel; Michael Karin
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

Review 9.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

10.  Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

Authors:  Henry Zall; Arnim Weber; Robert Besch; Niko Zantl; Georg Häcker
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.